Jazz Pharmaceuticals Fibromyalgia Potential Rejected by FDA

by | Oct 11, 2010 | Towing | 0 comments

Jazz Pharmaceuticals Fibromyalgia Potential Rejected by FDA

Jazz Pharmaceuticals shares slumped more than 5% in premarket trading Monday after the company announced that the FDA had denied approval for its fibromyalgia treatment, sodium oxybate. While approved to treat narcolepsy, sodium oxybate is illegally sold as the party and date rape drug GHB.

Continue reading Jazz Pharmaceuticals Fibromyalgia Potential Rejected by FDA

Jazz Pharmaceuticals Fibromyalgia Potential Rejected by FDA originally appeared on DailyFinance on Mon, 11 Oct 2010 09:10:00.

Filed Under: , ,

Permalink | Tweet this! | Comments

Submit a Comment